Selected article for: "mechanical ventilation and respiratory failure"
Author: Marty, Francisco M; Chemaly, Roy F; Mullane, Kathleen M; Lee, Dong-Gun; Hirsch, Hans H; Small, Catherine B; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R; Chien, Jason W; Dadwal, Sanjeet S
Title: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
  • Document date: 2019_12_3
    • ID: sl45z4i0_25
    Snippet: During the 28-day study period, 14/29 (48.3%) presatovirtreated patients and 12/28 (42.9%) placebo-treated patients required supplemental oxygen. Median (range) number of supplemental oxygen-free days was similar between presatovirtreated (26 [0-33] days) and placebo-treated (28 [0-30] days) patients (P = .84) ( Table 2 ). Three presatovir-treated patients (10.3%) and 3 placebo-treated patients (10.7%) developed respiratory failure requiring mech.....
    Document: During the 28-day study period, 14/29 (48.3%) presatovirtreated patients and 12/28 (42.9%) placebo-treated patients required supplemental oxygen. Median (range) number of supplemental oxygen-free days was similar between presatovirtreated (26 [0-33] days) and placebo-treated (28 [0-30] days) patients (P = .84) ( Table 2 ). Three presatovir-treated patients (10.3%) and 3 placebo-treated patients (10.7%) developed respiratory failure requiring mechanical ventilation through study day 28 (P = 1.0). No presatovir-treated patients and 2 placebotreated patients (7.1%) died through day 28 (P = .24) ( Table 2) ; 1 death was due to respiratory failure. Exploratory efficacy outcomes are described in Supplemental results.

    Search related documents:
    Co phrase search for related documents
    • efficacy outcome and respiratory failure: 1, 2
    • efficacy outcome and study period: 1, 2, 3, 4, 5, 6, 7
    • efficacy outcome and supplemental oxygen: 1, 2, 3
    • mechanical ventilation and placebo treat: 1, 2, 3, 4, 5
    • mechanical ventilation and respiratory failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mechanical ventilation and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mechanical ventilation and supplemental oxygen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mechanical ventilation and supplemental oxygen require: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • mechanical ventilation require and respiratory failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • mechanical ventilation require and study period: 1, 2, 3, 4, 5, 6, 7, 8
    • mechanical ventilation require and supplemental oxygen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • mechanical ventilation require and supplemental oxygen require: 1, 2, 3, 4, 5, 6
    • oxygen free day and supplemental oxygen: 1
    • oxygen free day and supplemental oxygen free day: 1
    • oxygen free day and supplemental oxygen free day number: 1
    • placebo treat and supplemental oxygen: 1, 2
    • respiratory failure and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • respiratory failure and supplemental oxygen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • respiratory failure and supplemental oxygen require: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10